Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients

This study has been completed.
Information provided by:
National Institutes of Health Clinical Center (CC) Identifier:
First received: February 21, 2003
Last updated: July 30, 2012
Last verified: July 2012
Results First Received: June 19, 2012  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Kaposi's Sarcoma
HIV Infections
HIV Seronegativity
Intervention: Biological: Bevacizumab

  Participant Flow

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Cohort 1: Cohort 1: Pts With HIV-associated Kaposi's Sarcoma 15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks
Cohort 2: Pts With Classic Kaposi's Sarcoma (HIV-uninfected) 15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks
Total Total of all reporting groups

Baseline Measures
   Cohort 1: Cohort 1: Pts With HIV-associated Kaposi's Sarcoma   Cohort 2: Pts With Classic Kaposi's Sarcoma (HIV-uninfected)   Total 
Overall Participants Analyzed 
[Units: Participants]
 17   2   19 
[Units: Participants]
<=18 years   0   0   0 
Between 18 and 65 years   15   2   17 
>=65 years   2   0   2 
[Units: Years]
Mean (Standard Deviation)
 42  (9.3)   58  (12.7)   50  (11) 
[Units: Participants]
Female   1   0   1 
Male   16   2   18 
Ethnicity (NIH/OMB) 
[Units: Participants]
Hispanic or Latino   3   0   3 
Not Hispanic or Latino   14   2   16 
Unknown or Not Reported   0   0   0 
Region of Enrollment 
[Units: Participants]
United States   17   2   19 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Response Rate   [ Time Frame: 36 months ]

2.  Secondary:   Number of Participants With Adverse Events   [ Time Frame: 70 months ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information